AMLX Projected Dividend Yield
Amylyx Pharmaceuticals Inc ( NASDAQ : AMLX )Amylyx Pharmaceuticals is a clinical stage biotechnology company. Co. is developing therapies for amyotrophic lateral sclerosis (ALS) and a range of other neurodegenerative diseases, including Alzheimer's Disease, Wolfram syndrome, Parkinson's Disease, Huntington's Disease, Progressive Supranuclear Palsy, Multi-System Atrophy, primary lateral sclerosis, ischemic stroke, multiple sclerosis, Friedreich's ataxia, and Leigh's syndrome. Co. is pursuing commercialization of AMX0035, which is a drug candidate for patients with ALS. AMX0035 is a dual unfolded protein response-Bcl-2 Associated X-protein apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid. 20 YEAR PERFORMANCE RESULTS |
AMLX Dividend History Detail AMLX Dividend News AMLX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |